Heart Failure Patients Registry A Prospective Observational Multicenter Registry of Patients With Chronic Heart Failure in the Population of the Russian Federation (PRIORITY-HF)

Registration

Registration

NCT04709263

Acronym

Priority-HF

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

19990

Start

2020-12-21

Primary completion

2024-03-28

Lead sponsor

AstraZeneca

Conditions

Heart Failure

Results posted

FALSE

Individual participant data sharing

YES

Registered primary outcomes

• Mean age [Baseline]
• Proportion of men and women [Baseline]
• Proportion of patients with negative lifestyle factors [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different etiology of CHF [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with a history of HF comorbidities and conditions of special interest [Baseline]
• Mean duration of comorbidities listed in previous paragraph (p. 5) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different chronic comorbidities [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with history of COVID-19 [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with vaccination [Baseline]
• Proportion of patients with different types of HF based on LVEF [Baseline]
• Proportion of patients with T2DM comorbid with different types of HF based on LVEF [Baseline]
• Mean HbA1c (for patients with T2DM) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF); [Baseline]
• Proportions of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different levels of HbA1c (for patients with T2DM) [Baseline]
• Mean BMI (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different BMI levels [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of CHF according to NYHA classification based on patient symptoms of HF [Baseline]
• Mean NT-proBNP level (or BNP) [Baseline]
• Mean heart rate (HR) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF); [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of HF according to SHOKS level [Baseline]
• Mean SBP (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with SBP [Baseline]
• Mean Diastolic blood pressure (DBP) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with DBP [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with concomitant CKD of different stages [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CKD and different levels of albumin-to-creatinine ratio in a spot urine sample [Baseline]
• Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hyperkalemia (K+ level >5,5 mmol/L) [Baseline]
• Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hypokalemia (K+ level <3,5 mmol/L) [Baseline]
• Mean LVEF (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Mean K+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Mean Na+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Mean hemoglobin level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different rhythm [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different QRS duration [Baseline]
• Proportion of patients receiving different classes of drugs for treatment of HF [Baseline]
• Proportion of patients with HFrEF with implantable devices [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with cardiac surgery and endovascular procedures [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving dual disease-modifying therapy [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving triple disease-modifying therapy [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving quadruple disease-modifying therapy [Baseline]
• Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CHF receiving different classes of glucose lowering drugs and their combinations for T2DM treatment [Baseline]